Effect of Simvastatin on Permeability in Cerebral Cavernous Malformation Type 1 Patients: Results from a Pilot Small Randomized Controlled Clinical Trial
Authors:
- 23 October 2019
- journal article
- letter
- Published by Springer Nature in Translational Stroke Research
- Vol. 11 (3) , 319-321
Abstract
No abstract availableFunding Information
- National Institute of Neurological Disorders and Stroke (U54 NS065705)
This publication has 13 references indexed in Scilit:
- Familial Cerebral Cavernous MalformationsStroke, 2019
- Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 DiseaseStroke, 2019
- Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH)Neurosurgery, 2018
- Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts PanelNeurosurgery, 2017
- RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous MalformationsStroke, 2017
- Dynamic Permeability and Quantitative SusceptibilityStroke, 2014
- Dynamic Contrast-Enhanced MRI Evaluation of Cerebral Cavernous MalformationsTranslational Stroke Research, 2013
- Rho Kinase Inhibition Rescues the Endothelial Cell Cerebral Cavernous Malformation PhenotypeJournal of Biological Chemistry, 2010
- Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrityJournal of Experimental Medicine, 2010
- The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPasesNature Medicine, 2009